Shots:

• The P-III COV-BARRIER substudy evaluates baricitinib + SoC vs PBO + SoC in 101 adult patients with COVID-19 who are on mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
• The results showed reduction in mortality (46% & 44%) @ Day 28 & 60. The findings are consistent with the reduction in mortality in the overall COV-BARRIER patient population
• Lilly plans to publish the results in a peer-reviewed journal in the coming mos. & share the data with regulatory authorities in the US- EU & other geographies. Additionally- FDA has broadened the EUA for baricitinib to allow treatment with or without remdesivir on Jul 28- 2021

 to   | Ref: PR Newswire | Image: Forbes